Zhijiang Biotech said at the 2026 semi-annual results briefing held on October 12 that as of the first half of 2026, the company's monetary capital was about 2,451 billion yuan, and it is carefully evaluating mergers, acquisitions, shareholding and cooperation opportunities in line with the company's direction around the integrated strategy of “prevention, diagnosis, and treatment”. In terms of target screening, the focus is on projects with high technical barriers and core competitiveness in the middle and upper reaches of the industrial chain. In terms of direction, it focuses more on fields such as tumor diagnosis, drug treatment, and upstream core raw materials, and forms collaboration with the company's existing layout of reagents, instruments, consumables and key raw materials. Currently, related projects are being actively connected.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.